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i
Executive Summary
Of  all the scientific discoveries regarding the subtle effects of  pollution on public health, 
few are more fundamentally troubling than the revelation that synthetic “endocrine 
disrupters,” ingested at very low doses, can turn males into females, disrupt fertility, and even 
render living things hermaphroditic.  These chemicals are in common use in the American 
marketplace, deployed as pesticides (DDT and atrazine), oral contraceptives, and building 
blocks for polycarbonate plastics and epoxy resins (bisphenol-A, or BPA).  By mimicking the 
effect of  critical hormones like estrogen, they can trigger biological responses at the wrong 
time or in damaging ways.
Scientists have known about BPA’s endocrine-disrupting potential since 
the 1930s, but what has only recently come into focus is its tendency to 
leach out of  plastics and cause adverse effects in animals. Its leaching 
effect was not fully understood until strange results occurred in two 
labs at opposite ends of  the country circa 1989.1  In one, a team at 
Tufts Medical School in Boston, Massachusetts was trying to find a 
natural inhibitor to the rapid growth of  breast cancer cells, while in 
the other, a team at Stanford University School of  Medicine in Palo 
Alto, California was researching the reactions of  estrogen-sensitive 
cells.  Tufts researchers Ana Soto and Carlos Sonnenschein discovered 
to their dismay that cells they did not expect to grow were multiplying 
rapidly, for no apparent reason.  Repeating their experiments over and 
over again for several months, they finally isolated the problem as a 
change in the components of  their laboratory equipment, specifically 
the manufacturer’s addition of  alkylphenol polyethoxylates containing 
BPA to the plastic in the centrifuge tubes where they had stored blood serum used in their 
experiments.  In a new line of  experiments, they discovered that injections of  the chemical 
into rats confirmed the chemical’s estrogen-mimicking capacity.  The Stanford scientist, 
David Feldman, similarly discovered that BPA in polycarbonate lab flasks used to sterilize 
water in his experiments was mimicking estrogen and causing abnormal cell growth.  
Two decades later a substantial body of  research suggests that, at very low doses, BPA 
causes reproductive disruption in rats and, most likely, in humans.  The substance is also 
ubiquitous, with one study showing its presence in the urine of  95 percent of  adults who 
participated in a Centers for Disease Control screening program called the National Health 
and Nutrition Examination Survey (NHANES).2  This research makes a compelling case 
that, in accordance with the precautionary principle embedded throughout American public 
health law, BPA and other synthetic endocrine-disrupting chemicals should be removed from 
consumer products, especially those used by women who may become or are pregnant, and 
their young babies post-delivery.   
Contents
Executive Summary ................................................1
Introduction ............................................................ 4
The Myth of  a Scientific Consensus on Safety ......... 5
The Good Laboratory Practices Myth ..................... 7
The Exposure and Metabolism Myths .................... 8
Economic Myths ................................................... 10
The Myth of  the Patchwork of  Regulations .......... 12
Working Toward a Solution:   
Broadening Narrow Jurisdictional Roles................ 14
Conclusion ............................................................ 16
Endnotes .............................................................. 17
About the Authors ............................................... 19
Page 2 Center for Progressive Reform
Myths and Truths in the Debate Over BPA Regulation
Despite the mounting evidence of  adverse health effects, plastics manufacturers are 
still doing their best to avoid or obscure these results and have launched an aggressive 
campaign to block federal agencies’ efforts to regulate BPA.  In fighting BPA regulation, the 
plastics industry is resorting to the same tactics used in the past by the manufacturers of  
cigarettes, automobiles, and pesticides, as well as many other industries determined to avoid 
government regulation:  influence and distort the findings of  federal science panels, attack 
academic science, publish and underwrite biased scientific research, and promote misleading 
information about the costs of  regulation.3
Their core mission in each of  these efforts is to undermine the validity of  the key hypothesis 
of  endocrinology—that the timing of  hormone exposure is at least as critical as the level of  
exposure.  Because synthetic chemicals that mimic estrogen can disrupt normal biological 
processes at very low doses, they must be evaluated under a different paradigm and with 
a different set of  assumptions than those traditionally applied to the better-characterized 
problem of  chemical carcinogens.  With chemical carcinogens, the axiom is that the “dose 
makes the poison” or, in other words, the greater the chemical exposure, the greater the 
cancer risk.  With endocrine disrupters, irreversible damage can occur at very low doses, not 
necessarily predictable by higher dose observations.
This paper reviews the major arguments advanced by the plastics industry in debates before 
federal agencies, state legislatures, and in any publication that will publish such self-interested 
speculation.4 In response to these myths—about the science, economics, and law related 
to BPA regulation—the paper explains what the scientific and policy literature actually says 
about BPA exposure.
 
The myth of  a scientific consensus on safety:  Industry advocates commonly assert that scientists concur that BPA is 
safe.  In fact, scientists agree that BPA is a known endocrine disruptor and that it is therefore unsafe.
The Good Laboratory Practices myth:  Industry activists argue that regulatory agencies should disregard studies that 
do not comply with FDA’s Good Laboratory Practices standard, including many studies that exhibit a link between low-
dose BPA exposure and adverse health effects.  In so doing, they misapply the GLP standard, which is focused primarily 
on recordkeeping and maintenance requirements, and is therefore not the best measure of  a particular study’s scientific 
validity.  It is a mistake to ignore the pioneering work that meets other standards of  quality, like robust peer review.
The exposure and metabolism myths:  BPA manufacturers would have us believe that the risk of  adverse effects 
from BPA exposure is insignificant because typical human exposures are low and the chemical is readily metabolized into 
non-endocrine-disrupting forms.  However, strong research shows that BPA’s ubiquity leads to such frequent doses that 
even healthy adults cannot metabolize all of  the chemical in their bodies.  Fetuses and infants, with their less developed 
metabolic systems, are at particular risk of  adverse health effects.
(continued)
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Conclusion and Recommendations  
Addressing toxic chemical risks at the federal level can produce significant public health 
benefits.  Achieving those benefits depends on federal agencies’ ability to develop a 
plan to coordinate information-gathering and regulatory activities to create a consistent, 
precautionary approach to regulation.  In the case of  BPA, it appears that the  
Environmental Protection Agency (EPA), Food and Drug Administration (FDA),  
and the National Institutes of  Environmental Health Sciences (NIEHS) and Occupational 
Safety and Health (NIOSH) are starting to coordinate their work, but that more could 
and should be done.  Congress could improve the federal approach to toxics regulations 
by affirmatively empowering agencies like the EPA, FDA, CPSC and OSHA to regulate 
endocrine-disrupting compounds.
 
The economic myths:  BPA manufacturers maintain that the chemical is a key ingredient in safe food packaging,  
one that cannot be replaced with economical alternatives.  In fact, numerous canned food companies have replaced  
BPA without significant cost problems, and BPA bans in Japan, China, and in various states in the U.S. have  
spurred innovation. 
The myth of  “patchwork” regulation:  The BPA-manufacturing industry complains that lack of  uniformity in  
state-level regulations increases the costs of  producing, distributing, and marketing their products.  Although a growing 
coterie of  states has banned the sale of  certain products with BPA, the truth is that non-regulation of  BPA is the norm 
across the United States.  The real purpose of  propagating this myth is to move the regulatory debate to the federal level, 
where large manufacturers’ advocates often have a stronger voice than their public interest counterparts.
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Introduction
The body’s endocrine glands do their work of  directing various bodily responses by secreting 
hormones into the bloodstream.  Glands distributed around the body play a major role in 
regulating metabolism, various reproductive functions, growth, and more.  The disruption  
of  these sensitive systems is extraordinarily time-sensitive.  If  a synthetic chemical mimicking 
a critical hormone like estrogen, but also triggering destructive rather than natural effects, 
enters the body while a fetus is developing in utero, it can cause irrevocable disruption  
of  the human reproductive system.  
The plastics industry and its trade associations have launched an aggressive campaign 
to block regulations that would protect the public from risks posed by the best-known 
endocrine disruptor—BPA.  They rely on arguments that ignore scientific research, overstate 
alleged economic hardships, and contradict wise public policy.  Their campaign has sought to 
advance five fundamental myths about BPA and its dangers. 
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Myths vs. Truths
The Myth of a Scientific Consensus on Safety
When the California General Assembly voted down a statewide ban on the use of  BPA 
in children’s products like baby bottles, sippy cups, and infant formula containers in 2008, 
the American Chemistry Council (ACC) issued a press release that misleadingly claimed: 
“Products targeted by this bill have been affirmed to be safe by government bodies around 
the world based on the science, most recently by the [Food and Drug Administration].”5  
This commonly heard refrain from plastics industry activists mischaracterizes the nuanced 
reports produced by government agencies like the Food and Drug Administration (FDA) 
and the European Food Safety Agency (EFSA), suggesting a clean bill of  health where it 
is not due.  Neither FDA nor EFSA has exonerated the chemical from the concerns about 
adverse health effects at low doses that have been documented by a robust body of  peer-
reviewed research.  
A more accurate description of  the state of  the science on BPA does not make for such a 
nice sound-bite.  To begin, it would note that FDA and the National Toxicology Program 
(NTP) have most recently expressed “some concern” about the potential effects of  BPA 
on the brain, behavior, and prostate gland of  fetuses, infants, and children.6  It would also 
acknowledge that FDA’s January 2010 public health recommendations endorse “reasonable 
steps to reduce exposure of  infants to BPA in the food supply,” both by supporting 
industry efforts to stop producing BPA-containing bottles and sippy cups and by facilitating 
development of  BPA-free linings for formula cans.7
BPA manufacturers and the activist groups they sponsor mischaracterize expert panels’ 
judicious work both by claiming that the panels have drawn the simplistic conclusion 
that BPA is “safe” and by suggesting that the panels’ conclusions are uniform.  When 
government agencies empanel experts to weigh in on the safety of  particular chemicals, 
they do not ask the experts to draw broad, policy-dominated conclusions about whether a 
chemical is “safe.”  Rather, the experts typically address more complex questions regarding 
their level of  concern about the likelihood of  a particular health effect manifesting itself  
from certain exposure levels for certain groups of  individuals.  For instance, FDA asked its 
expert panel to assess whether it should revise the appropriate level of  exposure to BPA 
from food contact applications.8  The panel concluded that the evidence was insufficient to 
support lowering the recommended exposure limit, not that BPA is “safe,” as ACC would 
lead people to believe.9  The National Toxicology Program’s Center for the Evaluation 
of  Risk to Human Reproduction (NTP/CERHR) asked a slightly different question—
whether BPA affects human reproduction or development.  The NTP/CERHR panel 
expressed concern that low-level exposures to BPA could have negative reproductive and 
developmental effects. 10  
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By oversimplifying the conclusions of  government-sponsored expert panels, BPA 
manufacturers and lobbyists seek to sell the myth of  scientific consensus to the public 
and to policymakers who lack the time or inclination to delve into the details of  scientific 
findings on BPA’s risks.  In doing so, they hope to forestall new regulation.  But this 
mischaracterization is rarely sufficient to carry the debate, so others follow.
Center for Progressive Reform Page 7
Myths and Truths in the Debate Over BPA Regulation
The Good Laboratory Practices Myth
Mindful that more than 90 percent of  Americans are thought to have detectable levels 
of  BPA in their bodies,11 BPA manufacturers and their trade associations have devoted 
considerable resources to undermining any new evidence that BPA can have adverse health 
effects at low doses.  Because measured concentrations are often low, BPA manufacturers 
hope to stanch significant regulatory limitations on production or use of  the chemical by 
casting doubt on the science of  low-dose health effects.  
Industry also knows that the simplest path for an agency facing the prospect of  having to 
regulate a chemical as ubiquitous as BPA without a specific mandate from Congress is to 
wait until the science is more fully developed.  Until then, industry’s approach is to seek 
to undercut scientific studies that demonstrate the danger of  their product.  Significantly, 
however, none of  the arguments the BPA industry has put forward in opposition to new 
knowledge about low-dose effects stands up to scrutiny.
The BPA industry’s frontal attack on low-dose toxicology seeks to dismiss sound scientific 
results on the grounds that low-dose effects have only been found in “small-scale 
experimental studies.”12 In this view, the only studies that are conducted according to a 
standard called Good Laboratory Practices (GLP) should be considered relevant to the 
debate.  This argument misperceives the purposes of  the GLP standard, which is to specify 
guidelines for the care of  laboratory animals, maintenance of  laboratory facilities, personnel 
requirements, and collection and storage of  raw data.13 That is, the GLP standard ensures 
that study results are verifiable and reproducible, regardless of  whether the underlying 
study is properly designed to answer questions relevant to the regulatory debate.  The GLP 
standard is not a measure of  whether a study is useful or not, or even if  is scientifically 
rigorous, as BPA supporters claim.
According to a group of  30 academic scientists writing in Environmental Health 
Perspectives in 2008, “GLP specifies nothing about the quality of  the research design, the 
skills of  the technicians, the sensitivity of  the assays, or whether the methods employed 
are current or out-of-date.”   In fact, conformance with the GLP standard is so immaterial 
to rating the quality of  a particular study that the FDA Science Board, an expert advisory 
committee, criticized FDA’s exclusion of  certain BPA studies for failure to meet the GLP 
standard, since those studies relied on the advanced, updated test procedures that are used 
at academic labs.14  As further evidence that compliance with GLP protocols is not an 
important factor in determining the validity of  a study, expert panels in Japan and Canada 
do not use GLP as a factor in weighing the relative value of  studies.15  Industry’s arguments 
about GLP standards are intended as a distraction from the findings of  studies that prove 
inconvenient to manufacturers.
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The Exposure and Metabolism Myths
When all else fails, BPA manufacturers, users, and their trade associations may concede 
that BPA poses an inherent hazard as an endocrine-disrupting chemical in the food supply, 
but then promote myths about exposures and metabolism in an effort to protect specific 
products.  For instance, ACC argues that the amounts of  BPA that can migrate from food 
containers into food “are minute, and well below safety standards set by government 
regulatory agencies around the world.”16  ACC also argues that “the very small amount of  
[BPA] that may be ingested by a person during normal daily activities is efficiently converted 
to biologically inactive metabolites, which are eliminated from the human body within 24 
hours.”17  Neither of  these arguments bears scrutiny.
The argument about ingested quantities not exceeding legal limits fails because the 
referenced legal safety standards are not completely health-protective.  That is precisely the 
point of  the debate – that new rules governing BPA are needed to reflect current science.  
Measured levels of  BPA in people’s blood may be low, but comparing those levels to “safety 
standards set by government regulatory agencies around the world” is inappropriate given 
the basis of  the regulatory agencies’ findings.  ACC cites the EFSA “safe intake level” of  
0.05 mg/kg-bw/day as the appropriate reference dose.  But ACC fails to note that the level 
was based on just two multi-generational reproductive toxicity studies in rats; one addressed 
changes in organ weight in adults and offspring, the other looked at liver effects in adult 
mice.  The reference dose was set in 2006.  In 2010, EFSA considered more than 800 other 
studies of  BPA and its potential effects that were published from January 2007 to July 
2010.  After reviewing this considerably richer range of  studies, EFSA echoed the concerns 
of  many other government bodies about BPA’s neurobehavioral effects, links to coronary 
heart disease and reproductive disorders, and potential enhancement of  sensitivity of  the 
mammary gland to dimethylbenzanthracene (DMBA)-induced carcinogenesis.  Despite these 
new concerns about adverse health effects related to BPA, EFSA made the controversial 
decision to retain the 0.05 mg/kg-bw/day reference dose.  Thus, ACC’s myth of  safe 
exposure levels only holds true to the extent that public health concerns about BPA are 
limited to organ weights and liver effects.
The myth that BPA is rapidly metabolized to biologically inactive compounds similarly 
glosses over important policy-relevant facts by ignoring science that does not comport with 
the myth.  ACC points to a single acute-exposure study in which six volunteers were fed 
one dose of  five milligrams of  BPA and then monitored for BPA and its metabolites in 
blood and urine for 96 hours.  The study’s authors, who have a history of  producing reports 
that seem to exonerate BPA, concluded that the entire dose of  BPA was metabolized to a 
compound called BPA-glucuronide, which is not an endocrine disruptor, and eliminated 
in urine.18  The five milligram acute dose in that study is not representative of  our typical 
exposures to the chemical, which occur almost continuously at much lower levels.  To be 
fair, the same authors found similar results when they dosed another set of  six volunteers 
with a much smaller dose of  BPA (25 micrograms).19  However, other studies, designed 
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to reflect real-world exposure scenarios, have produced different results.  For example, 
researchers interested in determining metabolism of  chronic BPA exposure modeled BPA 
urine concentrations as a function of  the time 1,469 participants spent fasting.  Their larger 
dataset was 
not consistent with the current consensus that BPA exposures are both rapidly 
cleared and almost entirely related to food intake.  Instead, it appears plausible that 
there is substantial nonfood exposure, accumulation in body compartments with long 
elimination times, or both.20
So, even granting ACC the point that BPA can be rapidly metabolized to biologically inert 
compounds, its argument loses relevance because of  the many and constant exposure 
pathways we face.  In addition, most of  the studies of  human BPA metabolism are based 
on the biological responses of  relatively healthy adults.  Fetuses, infants, and children have 
less developed systems for metabolizing environmental toxins and are more susceptible to 
the developmental impacts of  endocrine-disrupting chemicals.  Some evidence from animal 
studies suggests that human fetuses and neonates may not be able to metabolize BPA into 
an inactive form.21  And even in healthy adults, some researchers have discovered that certain 
body tissues can “de-conjugate” metabolized BPA, making it active again.22
A closer look at the exposure and metabolism myths reveals a bigger problem:  the dubious 
hypothesis that low doses of  BPA always induce fewer adverse consequences than high 
doses.  While the standard assumption with many toxic chemicals is that physiological 
reactions to the chemicals have a direct and “monotonic” relationship to exposures (i.e., 
as exposure to a chemical increases, so does the adverse health outcome), the endocrine 
system does not always work that way.  In fact, researchers have found “nonmonotonic 
dose response functions” when they have exposed pituitary, prostate cancer, and other 
cells to BPA.23  It is also worth noting that the estrogen receptors that BPA can bind to and 
activate are normally activated by minute levels of  natural hormones—at levels measured 
in picograms and nanograms per milliliter of  blood.  Numerous studies show human blood 
levels of  BPA in that range.24
As with the rest of  the scientific myths propounded by BPA manufacturers and their 
activist trade associations, the claims about the safety of  low-level exposure to BPA ignore 
significant and legitimate public health concerns that arise from ample scientific evidence.
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Economic Myths
Particularly during difficult economic times, industry has developed a practice of  hiding 
behind the specter of  financial ruin at the hands of  insensitive bureaucrats in order to stem 
the tide of  regulation.  The companies that manufacture BPA and their customers who 
use it to formulate plastics and epoxy resins have developed a slightly more nuanced—but 
much more distressing—approach, touting BPA’s allegedly crucial role in protecting the 
food supply.  As the North American Metal Packaging Alliance (NAMPA) readily points out, 
BPA-based epoxy can linings have the important characteristics of  being able to withstand 
the intense heat that companies use to kill bacteria in certain canned goods, being easily 
manipulated, extending shelf  life, and not imparting off-flavors in food—all at a relatively 
low cost.  They often intimate that restrictions on BPA in can linings could lead to spoiled or 
dangerous food.  For example, when interviewed for a 2010 Washington Post article on BPA 
alternatives, NAMPA’s chairman noted that “there hasn’t been a case of  food-borne illness 
resulting from a failure of  metal packaging since the industry began using BPA in its linings 
more than 30 years ago.”25
The objective of  such rhetoric is to suggest that policymakers must choose between BPA 
and an unsafe food supply.  The facts suggest otherwise.  Intense public pressure to abandon 
BPA in products like water bottles and canned foods has prompted many companies to seek 
out alternative solutions.  State-level bans on the sale of  BPA-containing children’s products, 
along with Japan’s limitations on BPA in can linings, are also promoting development of  
BPA alternatives.  With respect to can linings, it appears that reliable, durable alternatives 
exist for most foods.  A polyester compound has been identified as suitable for a wide range 
of  canning applications,26 and plant-derived “oleoresins” have also been adopted.27  High-
acid foods like tomatoes present a challenge because they can break down the BPA-free 
oleoresin linings, reducing shelf  life, but researchers are working on solutions.  With the 
development of  BPA-free products, a slight rift has developed in the messages from the likes 
of  ACC and NAMPA, on the one side, and downstream consumer goods companies, on the 
other.  Companies like Nalgene and Eden Foods, who cater to health-conscious consumers, 
market BPA-free products (water bottles and canned foods, respectively) and, unlike the 
chemical industry trade associations, they do not make claims about the chemical’s safety  
in the food supply.
Replacement costs are always a sticking point for new technologies, but alternatives to BPA 
have not proven to be as prohibitively costly as manufacturers and trade associations suggest. 
In fact, their estimates for replacing can linings ignore market factors that contribute to 
reducing costs of  replacement technologies, especially the effect of  economies of  scale.28  
The Japanese economic analysis for the phase-out of  school cafeteria tableware containing 
BPA was 127 yen per student per year, or approximately $1.10 in 2007 dollars.29  One 
company replaced its canned beans’ BPA-lined cans with a BPA-free alternative in 1999  
and found that using the BPA-free lining added just three to five cents to the retail prices.30  
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When regulation of  a toxic chemical might increase production costs, industry groups have 
consistently overstated cost estimates to challenge regulations.  For example, automakers 
argued that there were no suitable air pollution control technologies to control emissions of  
smog-forming nitrogen oxides, and acid-rain-producing sulfur dioxide from cars, and that 
fuel economy would suffer if  existing technologies were implemented.  But the incentives 
created by regulation led automakers to introduce catalytic converters, which resulted in 
substantial reductions in air pollution while increasing fuel economy at the same time.31   
Regulatory agencies rarely conduct retrospective analyses to verify the real world costs of  
regulation.  In the rare cases in which such analyses have been conducted, the ultimate 
compliance costs have often been proven to be only a fraction of  what was projected before 
a regulation was implemented.32
When 
regulation of a 
toxic chemical 
might increase 
production 
costs, industry 
groups have 
consistently 
overstated 
cost estimates 
to challenge 
regulations.
Page 12 Center for Progressive Reform
Myths and Truths in the Debate Over BPA Regulation
The Myth of the Patchwork of Regulations
Through tireless efforts and a web-savvy campaign, a grassroots coalition of  breast-
cancer-prevention advocates, environmentalists, concerned parents, and their allies have 
successfully lobbied for restrictions on BPA-containing products in Connecticut, Maryland, 
Massachusetts, Minnesota, Vermont, Washington, Wisconsin, several counties in New York, 
and the City of  Chicago. 33  Their success at the state and local level has prompted  
the plastics industry to resort to a myth of  a slightly different nature but no greater 
legitimacy than the myths discussed above:  they decry an allegedly incomprehensible 
“patchwork of  regulation.”  As tobacco and automobile manufacturers did in their own 
battles to avoid regulation, the BPA-manufacturing industry complains that lack of  
uniformity in state-level regulations increases the costs of  producing, distributing, and 
marketing their products.  They argue that uniform federal regulation provides a more 
predictable and economical business environment.
Federal regulation of  toxic substances can certainly produce significant benefits by 
protecting public health.  But the vast majority of  federal environmental laws establish a 
“floor” and not a “ceiling,” allowing the states to go beyond minimum national standards 
to protect their citizens.  In fact, state and local governments have often responded more 
quickly to emerging threats, serving as “laboratories of  democracy,” for the federal system.  
State-level toxics-control programs have often preceded federal programs with great success. 
One example in particular is California’s regulation of  polybrominated diphenyl ethers 
(PBDEs).  In 2003, California enacted a ban on penta- and octa-brominated diphenyl ether, 
two widely distributed PBDEs.  The ban took effect in 2008.34  At the time California 
banned the chemicals, the state of  the science on PBDEs paralleled the current knowledge 
about BPA:  scientists had evidence of  widespread human and environmental exposure, they 
had observed disruption of  normal hormonal processes in lab animals, but they continued 
to debate exactly what levels might be deemed “safe.”  But because substitutes were readily 
available, the only company to produce the chemicals in the U.S. began to phase out 
production within three months of  enactment of  the California ban.35  
Federal action to control exposures to PBDEs lagged behind, but is better informed  
because of  the California ban.  A year and a half  after the Great Lakes Chemical 
Corporation voluntarily stopped production of  the two PBDEs banned in California,  
EPA finally completed a rulemaking under TSCA that simply established a requirement for 
companies to notify the agency if  they want to produce or import the chemicals.36  In 2010, 
in response to evidence that the chemicals are still being found—perhaps even at elevated 
levels—in people’s bodies and in the environment despite the phase-out of  production  
and importation, EPA published a Chemical Action Plan for a broad class of  PBDEs.37    
The plan shows that EPA has developed a better agenda for addressing these chemicals’  
risks because state-level policies served as tests of  potential regulatory techniques.
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Compliance with heterogeneous state and local regulations is rarely too complicated for 
sophisticated product manufacturers and marketers.  History shows that manufacturers 
can work around inconsistent regulatory requirements, in the rare instances where such a 
“patchwork” exists.  For example, California’s Proposition 65 sets labeling requirements to 
inform consumers when products contain chemicals known to cause cancer, birth defects, 
or other reproductive harm.  The law only applies in California, but manufacturers have 
successfully created labels or new product formulations without major disruptions.38
BPA supporters’ real goal in presenting the myth of  “patchwork regulation,” is not to 
promote federal regulation, but to focus the regulatory debate inside the D.C. Beltway, 
where the plastics industry rightly believes it has the best chance of  beating back stronger 
regulation.  In Washington, BPA industry lobbyists and campaign contributors can focus  
on a smaller number of  decisionmakers.  Moreover, federal regulations are subject to 
numerous procedural and analytical requirements, providing BPA manufacturers with 
multiple opportunities to delay the process and introduce new and sometimes misleading 
information into regulatory proceedings.39  
By contrast, each of  these factors makes it more difficult for local and grassroots groups to 
engage effectively in the federal rulemaking process.  While they have relationships with local 
politicians and state legislatures, they often have only limited contact and influence  
with national politicians, who interact with a far greater number of  constituents, donors,  
and stakeholders than their local counterparts.  Funding, distance, and personnel constraints 
also limit the advocates’ ability to participate in agency deliberations, including public 
hearings and meetings.  For example, it is expensive, often prohibitively so, for grassroots 
activists to fly to Washington, D.C., to attend a public meeting or hearing.  It is even more 
difficult for grassroots activists to meet with agency staff  face-to-face.  The volume and 
technical detail involved in regulatory analyses raises the cost of  participation in the federal 
regulatory process, and causes some grassroots and public health advocacy groups to drop 
out of  the process.40  Preserving the availability of  state- and local-level toxics regulation 
thus preserves the possibility of  effective participation by as many voices as possible in the 
determination of  how to control dangerous chemicals.
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Working Toward a Solution:  Broadening 
Narrow Jurisdictional Roles
Despite the limitations of  the federal regulatory process to ensure broad and effective 
participation of  all stakeholders, addressing toxic chemical risks at the federal level can 
produce significant public health benefits.  Achieving those benefits depends on federal 
agencies’ ability to develop a plan to coordinate information-gathering and regulatory 
activities to create a consistent, precautionary approach to regulation.  In the case of  BPA, 
it appears that EPA, FDA, and the National Institutes of  Environmental Health Sciences 
(NIEHS) and Occupational Safety and Health (NIOSH) are starting to coordinate their 
work, but that more could and should be done.
BPA is, in essence, a test case of  how the government will respond to new evidence that 
particular chemicals disrupt the endocrine system.  A flood of  such evidence could soon 
be arriving, from EPA’s Endocrine Disruptor Screening Program, the Tox21collaboration 
between EPA, FDA, NIEHS, NTP, and others, and the European Union’s Registration, 
Evaluation, and Authorization of  Chemicals (REACH) program.  No doubt, when these 
programs uncover other potential endocrine-disrupting chemicals, the chemical industry’s 
activists will trot out the same arguments that they are currently using to avoid regulation of  
BPA.  We simply cannot afford for the government to respond in the way that it has to the 
debate over BPA—with tens of  millions of  dollars in research, repetitive advisory boards, 
and years of  delay—for every individual endocrine-disrupting chemical.  
Ideally, new evidence that a chemical is an endocrine disruptor would trigger a series  
of  regulatory actions.  To begin, EPA would conduct a screening-level exposure assessment 
using the TSCA Inventory, which would enable the agency to identify major manufacturers 
or importers of  the chemical.  EPA could also place the chemical on a TSCA § 5(b)(4) 
“chemicals of  concern list,” which would give EPA the authority to obtain information 
about smaller manufacturers and importers of  the chemical while also signaling to the 
public that the chemical may present an unreasonable risk of  harm to human health or the 
environment.41  The goal with these initial steps would be to start developing a better picture 
of  vulnerable populations and routes of  exposure.  EPA should also work with NIOSH to 
clarify the links between occupational and environmental exposures.  Ultimately, the goal 
of  this work should be to inform coordinated decisions by officials at EPA, FDA, OSHA, 
and CPSC regarding how each agency will use its existing authority and how all of  them will 
encourage state and local governments to be a part of  the regulatory solution.
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Federal toxic control laws are severely outdated, and leave significant room for legislative 
improvement.  Congress could improve the federal approach to toxics regulations by 
affirmatively empowering agencies like the EPA, FDA, CPSC and OSHA to regulate 
endocrine-disrupting compounds.  Although the statutes in place do not preclude these 
agencies from moving forward on modernizing their approach to endocrine disruptors, the 
agencies have been slow to adapt to new science about risks from toxic substances.  One 
significant hurdle to regulating endocrine disruptors is a failure to adopt new risk assessment 
guidelines that account for low-dose effects by encouraging exploration of  nonmonotonic 
dose-response relationships.  EPA, for example, took more than ten years to evaluate and 
adapt test procedures just to screen for endocrine disruptors.42  A 2007 National Academy 
of  Sciences report described a vision for modernized toxics testing, but contemplated a 20- 
to 30-year timeline for its implementation.43
EPA and other regulatory agencies should use caution when considering alternatives to BPA. 
It is important that any replacement for BPA not pose the same – or even more serious – 
public health hazards.  Based on what we know now about endocrine-disrupting compounds, 
EPA should take advantage of  new screening tools.  One particularly useful tool would be 
EPA’s Distributed Structure-Searchable Toxicity Database Network, which allows researchers 
and others to screen chemicals for potential toxicity based on similar chemical structures.
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Conclusion
Scientists and government panels have amassed enough evidence that BPA is a potentially 
harmful endocrine disruptor to move forward with controlling exposure from food contact 
applications.  As scientists develop a fuller picture of  other exposure pathways (e.g., 
transdermal exposure from thermal paper), agencies should adopt a precautionary approach 
to limiting exposures to BPA.  At the very least, the NTP and EPA should revise outdated 
exposure limits for BPA, by expanding the focus of  their risk assessments to a broad range 
of  potential adverse health effects.  The federal government should also encourage the 
adoption of  state and local regulations aimed at managing risks posed by BPA and other 
endocrine-disrupting chemicals.  As federal officials gather the evidence they need to meet 
the high burdens of  TSCA, the FDCA, the OSH Act, and other statutes, state and local 
regulation can provide some measure of  protection to the public while also supplying  
federal agencies with evidence for or against different regulatory options.   
The plastics industry is following a well-worn strategy to delay regulation of  BPA.   
The strategy relies on efforts to generate the perception that BPA does not pose a public 
hazard, coupled with efforts to contain regulatory action at the federal level, where  
the industry can influence the regulatory process most effectively.  Agencies and advocates 
should be accustomed to this pattern of  industry distortion and should filter it out of  the 
public dialogue.
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